Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending November 30, 2004. The report details a share repurchase transaction and updates regarding directors' interests in company shares and employee benefit plans.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only specific financial data disclosed relates to a share buyback:
- Shares Purchased: 885,000 Ordinary shares.
- Purchase Price: 1,127.7 pence per share.
- Transaction Date: November 29, 2004.
- Treasury Holdings Post-Transaction: 54,928,000 shares.
- Shares in Issue (excluding Treasury): 5,878,985,023 shares.
Material Changes
The primary material change reported is the reduction of outstanding shares through the purchase of 885,000 shares for Treasury. Additionally, there were minor adjustments in share holdings within employee benefit trusts:
- GSK Trust: Transferred 10,080 Ordinary Shares to participants in the SmithKline Beecham Employee Share Option Plan 1991.
- US Retirement Savings Plan: The number of Ordinary Share ADRs held by the fund decreased from 18,904,402 to 18,843,565 due to fund movements, with an average price of $42.77.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities.
Investor Verification Checklist
- Verify the total cost of the 885,000 share repurchase against the company's cash position in the most recent full financial report.
- Confirm the updated total share count and Treasury holdings in subsequent filings.
- Review the impact of the share buyback on earnings per share (EPS) in the next quarterly or annual report.
- Check for any further disclosures regarding the US Retirement Savings Plan ADR holdings.